Total dividende exercice 2018: € 1,210*

Dividende final

montant proposé
€ 1,210
date de l'approbation
avril 25, 2019
date ex-coupon
date du paiement
avril 30, 2019
Malheureusement, nous ne disposons pas encore de cette information en néerlandais. Maintenant, la version Anglais s'est affichée.

In-line with UCB’s long-term dividend policy, the Board proposes a gross dividend of € 1.21 per share (2017: € 1.18). If the dividend is approved by the Annual General Meeting on 25 April 2019, the net dividend of € 0.847 per share will be payable as of 30 April 2019 against the delivery of coupon #22.

Total dividende exercice 2017: € 1,180*

Dividende final

montant proposé
€ 1,180
date de l'approbation
avril 26, 2018
date ex-coupon
avril 27, 2018
date du paiement
mai 2, 2018
Malheureusement, nous ne disposons pas encore de cette information en néerlandais. Maintenant, la version Néerlandais s'est affichée.

De Raad van Bestuur van UCB stelt een dividend voor van € 1,18 per aandeel (bruto), een stijging van drie eurocent of 2,6%.

Coupon # 21
Ex-dividend: 27 April 2018
Record date: 30 April 2018
Payment: 2 May 2018

Total dividende exercice 2016: € 1,150*

Dividende final

montant proposé
€ 1,150
date de l'approbation
avril 27, 2017
date ex-coupon
avril 28, 2017
date du paiement
mai 3, 2017
Malheureusement, nous ne disposons pas encore de cette information en néerlandais. Maintenant, la version Anglais s'est affichée.

The Board of Directors proposes to pay a gross dividend of € 1.15 per share. If this dividend proposal is approved by the General Meeting on 27 April 2017, the net dividend of € 0.805 per share will be payable as of 3 May 2017 against the delivery of coupon #20. The shares held by UCB SA are not entitled to a dividend.

Per 4 January 2017, 191 426 122 UCB shares are entitled to a dividend, representing a total distribution of € 220 million. This amount may fluctuate depending the number of UCB shares held by UCB SA on the dividend approval date. The Board of Directors will communicate at the general meeting the total number of UCB shares entitled to a dividend and will submit the aggregate amount to be distributed for approval. The annual accounts of 2016 will be adapted accordingly.

Total dividende exercice 2015: € 1,100*

Dividende final

montant proposé
€ 1,100
date de l'approbation
avril 28, 2016
date ex-coupon
avril 29, 2016
date du paiement
mai 3, 2016
Malheureusement, nous ne disposons pas encore de cette information en néerlandais. Maintenant, la version Anglais s'est affichée.

The gross dividends paid in 2015 and 2014 were €205 million (€1.06 per share) and €202 million (€1.04 per share) respectively.

A dividend in respect of the year ended 31 December 2015 of €1.10 per share, amounting to a total dividend of €210 million, is to be proposed at the annual general meeting of the shareholders on 28 April 2016.

In accordance with IAS 10, events after the reporting period, the proposed dividend has not been recognized as a liability at year-end.

Coupon nr. 19

Total dividende exercice 2014: € 1,060*

Dividende final

montant proposé
€ 1,060
date de l'approbation
avril 30, 2015
date ex-coupon
mai 4, 2015
date du paiement
mai 6, 2015
Malheureusement, nous ne disposons pas encore de cette information en néerlandais. Maintenant, la version Néerlandais s'est affichée.

De raad van bestuur van UCB stelt een dividend voor van € 1,06 per aandeel (bruto), een stijging van twee eurocent of 2%

Coupon nr. 18

L'histoire des dividendes

événements financiers

Information de l'entreprise

Malheureusement, nous ne disposons pas encore de cette information en néerlandais. Maintenant, la version Anglais s'est affichée.

Source: company website, April 2018

UCB is a global biopharmaceutical company, with a focus on neurology and immunology.

Our business is strong. Total revenue grew to €4.5 billion in 2017. We are more than 7,500 people in all four corners of the globe, inspired by patients and driven by science.

Looking ahead, we have a solid platform for continuous growth with our core products Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and we are preparing the launch of a potential medicine to help patients with osteoporosis. At the same time, we are very excited about the progress in our early research pipeline.

Politique de dividende

Malheureusement, nous ne disposons pas encore de cette information en néerlandais. Maintenant, la version Anglais s'est affichée.

Source: company website, April 2018

The Board of Directors intends to continue to sustain a dynamic dividend policy, consistent with the long term growth prospects of the Company, offering gradual increase in dividend, and as far as possible not to reduce it, irrespective of the short term income variations.